Mylan’s Complex Product Success Is Offset by Generic Industry Headwinds
We plan to lower our fair value estimate for Mylan after the company reported weaker-than-expected fourth-quarter performance. Although a number of recent product launches like Fulphila (biosimilar Neulasta) and Wixela (generic Advair) help keep our forecast for $12.1 billion in revenue for this year near the midpoint of guidance, our adjusted EPS estimate falls just above the high end of management’s goal for between $3.80 to $4.80. Although we expected some margin pressure from generic competi...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.